非小细胞肺癌新辅助治疗的进展  

Progress in neoadjuvant therapy of non-small cell lung cancer

作　　者：史湖波[1] 徐祎慧[2] SHI Hubo;XU Yihui(Department of Thoracic Surgery,Shandong Provincial Chest Hospital,Shandong Province,Ji’nan 250013,China;Department of Laboratory,Ji’nan Central Hospital,Shandong Province,Ji’nan 250010,China)

机构地区：[1]山东省胸科医院胸外科,山东济南250013 [2]济南市中心医院检验科,山东济南250010

出　　处：《中国医药导报》2021年第3期43-47,共5页China Medical Herald

基　　金：山东医药卫生科技发展计划项目(2016WS0130);山东省济南市科技计划项目(201907117)。

摘　　要：肺癌是全世界发病率与死亡率均居于首位的恶性肿瘤,其中非小细胞肺癌(NSCLC)是最常见的类型。目前胸部CT在临床、查体的广泛应用,越来越多的早期肺癌得以发现,但仍有较多的中晚期肺癌患者。对于局部晚期NSCLC患者,术后的辅助治疗,包括放化疗、免疫治疗、靶向治疗已被证明可以显著改善患者的预后。最新的研究显示,术前的新辅助治疗手段,具有良好的耐受性和治疗依从性,并未增加手术的并发症及死亡风险,同时提供了更多可手术治疗的机会,减少了疾病复发率,提高整体治愈率。同时这些新辅助治疗手段的联合应用试验也在进行中,其结果令人期待。本文就NSCLC不同新辅助治疗的效果进行探讨,将其最新进展进行综述,为临床研究提供参考。Lung cancer is a malignant tumor with the highest morbidity and mortality in the world,and non-small cell lung cancer(NSCLC)is the most common type.At present,chest CT is widely used in clinical and physical examinations,and more and more early lung cancers are found,but there are still more patients with advanced lung cancer.For patients with locally advanced NSCLC,postoperative adjuvant treatments,including radiotherapy and chemotherapy,immunotherapy,and targeted therapy have been shown to significantly improve the prognosis of patients.The latest research shows that the preoperative neoadjuvant treatment has good tolerance and treatment compliance,does not increase the risk of complications and death of surgery,and provides more opportunities for surgical treatment and reduces disease recurrence,while improves the overall cure rate.At the same time,the combined application trials of these neoadjuvant treatments are also underway,and the results are expected.This article discusses the effects of different neoadjuvant treatments for NSCLC,reviews its latest developments,and provides references for clinical research.

关 键 词：非小细胞肺癌 新辅助治疗 放疗 化疗 免疫治疗 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]